Format

Send to

Choose Destination
Int J Pharm. 2016 Dec 30;515(1-2):757-773. doi: 10.1016/j.ijpharm.2016.11.002. Epub 2016 Nov 6.

Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects.

Author information

1
Univ Lyon, CNRS, UMR-5007, LAGEP, F-69622, Lyon, France; Faculty of Pharmacy, Kabul University, Kabul, Afghanistan.
2
Univ Lyon, CNRS, UMR-5007, LAGEP, F-69622, Lyon, France.
3
Faculty of Pharmacy, Kabul University, Kabul, Afghanistan.
4
Faculty of Sciences, Lebanese University, Lebanon.
5
Univ Lyon, CNRS, UMR-5007, LAGEP, F-69622, Lyon, France. Electronic address: elaissari@lagep.univ-lyon1.fr.

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs. Debilitating diseases such as rheumatoid arthritis and osteoarthritis are commonly managed by NSAIDs. However, NSAIDs pharmacological mechanism is often associated with the presence of gastrointestinal side effects. NSAIDs encapsulation is performed in order to overcome some of the drawbacks linked to their clinical use. To fulfill this purpose, various vectors like polymer-based nanoparticles, liposomes and solid lipid nanoparticles have been proposed. Such vehicles could have advantages but some limitations as well. This manuscript highlights current NSAIDs encapsulation approaches based on either preformed polymers or lipids. Moreover, properties of the prepared carriers and their applications are also discussed. Many factors are taken into account for selecting carrier type and encapsulation method. It was concluded that different vehicles and preparation methods have been employed for NSAIDs encapsulation. Mostly, vehicles sizes ranged within the nanoscale. Main advantages that have been confirmed by in vitro and in vivo studies include promoted stability, sustained release and bioavailability enhancement.

KEYWORDS:

Carriers; Encapsulation; In vivo; Liposomes; Non-steroidal anti-inflammatory drugs; Particles; Solid lipid nanoparticles

PMID:
27829170
DOI:
10.1016/j.ijpharm.2016.11.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center